NRG Pathology Committee is responsible for providing the pathology and biomarker testing expertise needed to optimize the evaluation, design and execution of clinical trials, translational science projects, and educational activities undertaken by NRG Oncology. This meeting discusses topics related to accomplishing these missions.

12:00 – 12:10  Committee Membership, Organization, and Responsibilities Update  
(Simko / Lucas)

12:10 – 12:20  Reports from Pathology Representatives for their Disease Sites  
(Clinical Trials, Translational Science).

12:20 – 12:50  “Digital Pathology & Clinical Trials”  
(Michael Bonham, PhD, MD - Proscia, Inc.)

12:50 – 1:00  Closing/Questions/Comments  
(Simko / Lucas)
NRG Oncology Pathology Committee

Jeffrey Simko, Peter Lucas, William Rodgers

Friday, January 10, 2020 / 12-1pm
CDT Marriott Marquis Houston
Chambers, 2nd Level
Agenda

• **Organization and Responsibilities Update** (Simko, Lucas & Rodgers)

• **Disease (Organ) Site Updates** (All)

• **Visitors Presentation:** “Digital Pathology in Clinical Trials”  Michael Bonham, MD, PhD, CMO of Proscia Biosciences

• **Any Additional Business or Updates** (All)
Digital Pathology Advantages in Clinical Trials

Scan entire case instead of representative slide.
  Reduced logistics, increase access, more comprehensive image library, etc.

Research tool for development of new image-based biomarkers.
  Image analysis and artificial intelligence research (Digital Image Biomarkers; DIBs)

Applications to Clinical Trial Design and Proper Patient Selections.
  Integral DIBs (e.g. digital Oncotype, Decipher, MSI, etc.)
Digital Pathology Roadblocks / Issues

Scanning Infrastructure
Sites scanning their cases, data storage, access, etc.

Access Issues: NCI control or Trial Group Control?
Navigator?

Biomarker Development Teams
Who is going to do all of this?